UBS Group’s Lichen China LICN Stock Holding History

UBS Group’s Portfolio LICN Stock Details LICN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$134K	Buy	135,167 +135,000	+80,838%	+$500K	﹤0.01%	7018
2026 Q1	$985	Sell	167 -73	-30%	-$240	﹤0.01%	9666
2025 Q4	$677	Sell	240 -4,106	-94%	-$14.8K	﹤0.01%	9849
2025 Q3	$19K	Sell	4,346 -2,705	-38%	-$12.1K	﹤0.01%	8183
2025 Q2	$29.1K	Buy	7,051 +6,704	+1,932%	+$28.5K	﹤0.01%	8181
2025 Q1	$1.34K	Sell	347 -829	-70%	-$12.8K	﹤0.01%	9534
2024 Q4	$41.9K	Buy	1,176 +1,083	+1,165%	+$319K	﹤0.01%	7403
2024 Q3	$33.6K	Sell	93 -38	-29%	-$14.6K	﹤0.01%	7067
2024 Q2	$38.2K	Buy	+131	New	+$33.6K	﹤0.01%	6895
2024 Q1	–	Sell	-3	Closed	-$1.3K	–	9720
2023 Q4	$1.3K	Sell	3 -8	-73%	-$2.42K	﹤0.01%	8346
2023 Q3	$2.66K	Sell	11 -16	-59%	-$3.32K	﹤0.01%	7667
2023 Q2	$7.15K	Buy	27 +10	+59%	+$4.17K	﹤0.01%	7319
2023 Q1	$7.31K	Buy	+17	New	+$7.96K	﹤0.01%	7818

Other funds holding LICN

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's LICN Position: Q2 2026 in Review

UBS Group increased its Lichen China (LICN) stake by 80,838% in Q2 2026, buying an estimated $500K and bringing the position to 135,167 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #7018.

UBS Group first reported a position in LICN in Q1 2023 and has held it in 13 quarters since. 3 funds tracked by Wall St. Rank hold LICN as of Q2 2026.

UBS Group held 135,167 shares of Lichen China worth $134K as of Q2 2026.
UBS Group bought 135,000 Lichen China shares in Q2 2026, an estimated $500K.
Lichen China made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7018 holding.
UBS Group first reported a position in Lichen China in Q1 2023 and has held it in 13 quarters since.
3 funds tracked by Wall St. Rank held Lichen China as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.